Spinal Muscular Atrophy

New England CEPAC

ICER developed a report assessing the comparative clinical effectiveness and value of onasemnogene abeparvovec (Zolgensma®, Novartis AG/AveXis) and nusinersen (Spinraza®, Biogen) for treatment of spinal muscular atrophy (SMA).

For questions, please contact Matt Seidner, Program Director, at mseidner@icer-review.org.

Key Dates

Associated Materials